About: Clinical application of Chemiluminescence Microparticle Immunoassay for SARS-CoV-2 infection diagnosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical application of Chemiluminescence Microparticle Immunoassay for SARS-CoV-2 infection diagnosis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Clinical application of Chemiluminescence Microparticle Immunoassay for SARS-CoV-2 infection diagnosis
Creator	Liu, Lei Zhang, Ying Ding, Yinjuan Kou, Guomei Liu, Wanbing »more»
source	Elsevier; Medline; PMC
abstract	BACKGROUND: The unsatisfactory accuracy and capacity of real time RT-PCR depends on several unavoidable reasons, which cannot meet the demands for COVID-19 diagnosis. METHODS: 206 serum samples were collected from patients who were treated in the General Hospital of the Central Theater Command of the PLA between January 18 and April 4, 2020. 270 serum samples from healthy blood donors were used as control. IgM and total antibodies (Ab) against SARS-CoV-2 were detected by Chemiluminescence Microparticle Immunoassay (CMIA). RESULTS: Among the 206 patients, the positive rate of IgM and Ab were 149/206 (72.3 %) and 187/206 (90.8 %), respectively. And the specificity of IgM and Ab detection were 99.3 % and 98.9 %, respectively. The sensitivity of CMIA for Ab detection was significantly higher than that of IgM. An increase of the positive rate and S/CO value for detecting IgM and Ab accompanied with the increasing of days post-disease onset (d.p.o.) were observed. The positive rate of Ab detected by CMIA increased rapidly after 7 d.p.o., while that of IgM was obviously increased after 14 d.p.o.. In addition, the age and gender of these patients did not affect the seroconversion and titer of antibodies during the whole course. The disease-severity of patients had no effect on the seroconversion of antibodies. However, the critical patients possessed a much higher antibody titers than the no-critical cases after 14 d.p.o.. CONCLUSIONS: The CMIA can provide important complementation to nucleic acid assay and help to enhance the accuracy and capacity of diagnosis of SARS-CoV-2 infection.
has issue date	2020-08-01(xsd:dateTime)
bibo:doi	10.1016/j.jcv.2020.104576
bibo:pmid	32763810
has license	no-cc
sha1sum (hex)	924a62ecb3a548da26c3e790c134f6877e70cc0f
schema:url	https://doi.org/10.1016/j.jcv.2020.104576
resource representing a document's title	Clinical application of Chemiluminescence Microparticle Immunoassay for SARS-CoV-2 infection diagnosis
has PubMed Central identifier	PMC7395231
has PubMed identifier	32763810
schema:publication	J Clin Virol
resource representing a document's body	covid:924a62ecb3a548da26c3e790c134f6877e70cc0f#body_text
is schema:about of	named entity 'antibody' named entity 'levels' named entity 'depends' named entity 'IgM' named entity 'positive' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software